Kratos Research Labs

KRL10 RUO launch access: documentation-led small-order review, product docs, and gated catalog access after RUO acknowledgement. Send KRL10 review request. Research use only; not for human or veterinary use.

Author: mollybolt

  • What Does the Published Research Say About KPV?

    Research Context

    • The packet comprises four human-study sources, one review, and several preclinical reports (cell, animal, and delivery/formulation). The human-study sources in this packet are not KPV intervention trials and do not establish KPV-specific clinical efficacy [pubmed:36175155; pubmed:35320643; pubmed:35830641; pubmed:40935835].
    • The strongest conclusions should remain anchored to the specific populations/endpoints actually studied; do not generalize beyond those contexts. Parts of the evidence base are preclinical, limiting translational certainty.
    • Dosing and systemic safety are not established by this packet and should not be inferred.

    Evidence map (packet-level):

    • Human-study sources: 4 (not KPV interventions)
    • Review sources: 1 (contextual, not KPV-specific efficacy)
    • Preclinical sources: multiple (in vitro, animal, delivery/formulation, structural/materials)

    Key Takeaway

    Most evidence for KPV in this packet is preclinical. There are no KPV-specific human interventional outcomes here; mechanistic cell studies, animal models, and delivery work should not be interpreted as clinical efficacy, dosing guidance, or safety evidence.

    Direct Answer

    • This packet provides no KPV-specific human interventional outcome data. Available findings are predominantly preclinical: in vitro anti-inflammatory signaling, animal-model barrier findings using a KPV-binding hydrogel, transdermal and colon-targeted delivery studies, and peptide self-assembly/nanomaterial work [pubmed:40073467; pubmed:22837805; pubmed:35245681; pubmed:19909746; pubmed:28343991; pubmed:39252648].
    • Review content offers disease-context framing but is not evidence of KPV efficacy [pubmed:28806188]. Bottom line: human efficacy for KPV is not established in this packet.

    Human Evidence in the Packet (Context Only; Not KPV Trials)

    • [pubmed:36175155] International consensus recommendations for adrenoleukodystrophy (ALD) diagnosis/management. Not a KPV study; no KPV interventional outcomes.
    • [pubmed:35320643] Hydrocortisone in preterm infants (survival without bronchopulmonary dysplasia). Not a KPV study; no KPV interventional outcomes.
    • [pubmed:35830641] Erythropoietin trial for neonatal hypoxic-ischemic encephalopathy. Not a KPV study; no KPV interventional outcomes.
    • [pubmed:40935835] Mechanistic work on NLRP3 autophagic degradation disruption in melanocytes relevant to vitiligo pathobiology. This is disease-mechanistic context, not a KPV intervention or clinical outcome study.

    Interpretation: These human-study citations are included in the packet but do not establish KPV clinical efficacy. Conclusions regarding KPV should not be extrapolated from these unrelated human studies.

    Review Context (Not KPV-Specific)

    • [pubmed:28806188] Review of tubulointerstitial nephritis and uveitis (TINU). Provides context on ocular inflammatory mechanisms/disease but is not about KPV and should not be used as evidence of KPV efficacy.

    Preclinical and Mechanistic Evidence

    • In vitro (cellular) findings
    • [pubmed:40073467] In vitro human keratinocyte culture: KPV mitigated fine dust–induced apoptosis and inflammatory signaling by regulating oxidative stress and modulating MAPK/NF-κB pathways.
    • [pubmed:22837805] In vitro human bronchial epithelial cells: melanocortin-related peptides (including KPV-related mechanisms) inhibited inflammatory cues; implicated MC3R-related pathways. These are mechanistic cellular data, not clinical outcomes.
    • Animal models and tissue-level preclinical work
    • [pubmed:35245681] A KPV-binding double-network hydrogel restored gut mucosal barrier measures in an inflamed colon mouse model (animal study). No human outcomes were evaluated.
    • [pubmed:19909746] Colon-targeted drug-loaded nanoparticles within polysaccharide hydrogels reduced colitis severity in a mouse model (preclinical delivery concept relevant to peptide interventions). Not KPV-specific efficacy.
    • Delivery/formulation and nanomaterials
    • [pubmed:28343991] Transdermal iontophoretic delivery of KPV across ex vivo microporated human skin demonstrated permeation under iontophoresis (delivery/permeation study). This is not evidence of systemic exposure or clinical efficacy.
    • [pubmed:39252648] KPV and rapamycin self-assembled into carrier-free nanodrugs evaluated for vascular calcification therapy in preclinical systems (nanomaterials/preclinical; no human outcomes).
    • Structural/materials and related context
    • [crossref:10.1211/0022357011776360] Conformational analysis of Ac-Lys-Pro-Val-NH2 (KPV motif) provides structural context (structural/biophysical; not efficacy).
    • [crossref:10.1021/acs.biomac.5c01800.s001] Self-assembly of Pro-Val-Pro-Val into nanoporous peptide frameworks (materials science; not KPV-specific efficacy).
    • [crossref:10.1271/bbb.80473] Transepithelial transport characteristics of a non-KPV antihypertensive hexapeptide in Caco-2 monolayers (analog/transport context; not KPV-specific).
    • [pubchem:125672] Compound record for MSH(11–13) fragment (Lys-Pro-Val/KPV) (database record; structural/identifier context).
    • [crossref:10.1021/acs.jafc.3c02918.s001] Neuroprotection/gut microbiota study of a selenopeptide distinct from KPV (non-KPV; excluded from efficacy discussion).
    • Unrelated preclinical citation included in the packet
    • [pubmed:37161053] Vimentin required for tumor progression/metastasis in a mouse NSCLC model (preclinical/oncology). This study is unrelated to KPV and should not be interpreted as informing KPV.

    Limitations and Uncertainties

    • No KPV-specific human interventional outcome trials are present in the packet; clinical efficacy for any indication is not established here.
    • Dosing, systemic exposure, and safety are not resolved by the packet and should not be inferred.
    • Preclinical (cell/animal) and delivery/formulation findings may be mechanistically or translationally interesting but do not constitute human clinical outcomes.
    • Mechanistic plausibility or materials advances should not be reframed as proven clinical benefit without appropriately designed human trials.

    Bottom line: based on this packet, KPV lacks established human efficacy, and no dosing or safety conclusions can be drawn.

    FAQ

    • Are there any human trials showing KPV works for a specific condition?
    • No. This packet contains no KPV-specific human interventional outcomes [pubmed:36175155; pubmed:35320643; pubmed:35830641; pubmed:40935835].
    • What mechanisms has KPV shown in lab studies?
    • In vitro, KPV reduced oxidative stress–linked apoptosis and inflammatory signaling in human keratinocytes and modulated MAPK/NF-κB; melanocortin-related peptides also inhibited inflammatory cues in human bronchial epithelial cells with a role for MC3R [pubmed:40073467; pubmed:22837805].
    • Are there animal data relevant to KPV?
    • A KPV-binding hydrogel improved gut barrier measures in an inflamed colon mouse model; colon-targeted nanoparticle hydrogels reduced colitis in mice (not KPV-specific) [pubmed:35245681; pubmed:19909746]. These are preclinical findings only.
    • Does KPV cross the skin or target the vasculature based on current studies?
    • Ex vivo iontophoretic delivery showed KPV permeation across microporated human skin (delivery study), and KPV co-assembled with rapamycin into nanodrugs evaluated preclinically for vascular calcification; neither demonstrates human exposure or efficacy [pubmed:28343991; pubmed:39252648].
    • Does this packet inform dosing or safety for KPV?
    • No. The packet does not establish dosing, systemic exposure, or safety for KPV.

    References

    • Human-study/context citations: [pubmed:36175155]; [pubmed:35320643]; [pubmed:35830641]; [pubmed:40935835].
    • Review (context only): [pubmed:28806188].
    • Preclinical in vitro/cellular: [pubmed:40073467]; [pubmed:22837805].
    • Preclinical animal/tissue-level: [pubmed:35245681]; [pubmed:19909746].
    • Delivery/formulation/nanomaterials: [pubmed:28343991]; [pubmed:39252648].
    • Structural/materials/records: [crossref:10.1211/0022357011776360]; [crossref:10.1021/acs.biomac.5c01800.s001]; [crossref:10.1271/bbb.80473]; [pubchem:125672]; [crossref:10.1021/acs.jafc.3c02918.s001] (non-KPV).

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About GHK-Cu?

    What Does the Published Research Say About GHK‑Cu?

    Research Context

    • The supplied packet contains one human/clinical study, several review articles, and multiple preclinical/mechanistic reports. Conclusions below are limited to the packet and its uncertainties.
    • Reviews are used to frame mechanisms and translational hypotheses; they do not substitute for primary human outcome evidence [pubmed:29986520; pubmed:35083444; pubmed:26236730; pubmed:39963574; pubmed:41490200; pubmed:41476424].
    • Animal, in vitro, and biochemical findings are separated from human conclusions and should not be presented as established clinical outcomes.
    • The human/clinical label for the cited study follows the packet’s classification; study design specifics (e.g., endpoints, randomization) are not provided here.

    Key Takeaway

    Direct human evidence is narrow (smoke‑related skeletal muscle dysfunction). Broader “regenerative” or “anti‑aging” narratives are review‑driven or preclinical and remain hypothesis‑generating.

    Direct Answer

    • Human evidence in this packet is limited to one study in the context of cigarette smoke–related skeletal muscle dysfunction; a SIRT1‑dependent pathway is proposed but not established as causal in humans [pubmed:36905132].
    • Broader narratives about regeneration, dermatology, or anti‑aging are largely review‑driven and supported by preclinical models; they are hypothesis‑generating rather than confirmatory [pubmed:29986520; pubmed:35083444; pubmed:26236730; pubmed:39963574; pubmed:41490200; pubmed:41476424].
    • The packet does not justify dosing or generalized safety conclusions.

    Human evidence (primary)

    • One study classified in the packet as human/clinical addresses GHK‑Cu in a cigarette smoking–related skeletal muscle dysfunction context and reports effects in that setting. The authors propose a SIRT1‑dependent pathway, which should be treated as an associated/proposed mechanism rather than confirmed human causality based on the packet alone. Specific endpoints and cohort details are not provided in the packet and are therefore not extrapolated here [pubmed:36905132].

    Review (context)

    • Reviews synthesize mechanistic and translational themes for GHK and GHK‑Cu, including regenerative/protective actions and potential relevance to skin biology and aging; these do not replace primary human outcome data [pubmed:29986520; pubmed:35083444; pubmed:26236730; pubmed:39963574].
    • Two reviews serve as broader overviews of peptide therapies (orthopaedic and injectable therapy primers) rather than GHK‑specific clinical outcome syntheses; they are used here for general context only [pubmed:41490200; pubmed:41476424].
    • Age‑related serum GHK level figures (e.g., ~200 ng/mL at ~20 years, ~80 ng/mL at ~60 years) are review‑derived and should not be treated as definitive population surveillance; they are not used to draw clinical conclusions here [pubmed:35083444].

    Preclinical and mechanistic evidence

    • Pulmonary models
    • Silicosis model: attenuation of lung inflammation and fibrosis with a proposed PRDX6 target [pubmed:38879894].
    • Cigarette smoke–induced emphysema/inflammation: effects associated with oxidative‑stress pathways [pubmed:35936787].
    • Gastrointestinal model
    • Experimental colitis: reports of beneficial effects with mechanistic exploration [pubmed:40672369].
    • Zebrafish inflammation model
    • Attenuation of CuSO4 or LPS‑induced inflammation in larvae [pubmed:41997403; crossref:10.1016/j.ejphar.2026.178880].
    • Biomaterials/local delivery (experimental)
    • GHK‑Cu loaded into hydroxyapatite microspheres for localized anti‑inflammatory/antioxidant purposes in experimental systems [pubmed:40716276].
    • Chemistry and binding (biochemical/in vitro)
    • Copper(II) binding to GHK (DFT study) [crossref:10.22144/ctu.jen.2018.052].
    • Fluorescent chemosensor development based on GHK [crossref:10.1021/ol0101638; crossref:10.1002/chin.200208210].
    • Stimulation of sulfated glycosaminoglycan synthesis by GHK‑Cu (biochemical context) [crossref:10.1016/0024-3205(92)90504-i].
    • Identity and records (ancillary)
    • PubChem compound entry for GHK [pubchem:73587].
    • Patent search indicating commercial interest; not efficacy evidence [patent_search:ghk-cu-copper-tripeptide-1-glycyl-l-histidyl-l-lysine].

    Limitations and open questions

    • Translational certainty remains limited: animal/in vitro findings do not establish human efficacy [pubmed:38879894; pubmed:35936787; pubmed:41997403; pubmed:40672369; pubmed:40716276].
    • Human evidence is sparse and context‑specific; conclusions should remain anchored to the smoking‑related skeletal muscle dysfunction domain studied [pubmed:36905132].
    • Reviews provide useful context but cannot substitute for clinical outcome trials [pubmed:29986520; pubmed:35083444; pubmed:26236730; pubmed:39963574; pubmed:41490200; pubmed:41476424].
    • Dosing, safety, and generalizability are not established by the supplied evidence.
    • Because copper binding alters peptide chemistry, findings for GHK versus GHK‑Cu may not be interchangeable across studies; check the form investigated in each report [crossref:10.22144/ctu.jen.2018.052; crossref:10.1021/ol0101638; crossref:10.1016/0024-3205(92)90504-i].

    FAQ

    • What human clinical evidence exists for GHK‑Cu?
    • The packet includes one human/clinical study focused on cigarette smoke–related skeletal muscle dysfunction; a SIRT1‑dependent mechanism is proposed but not confirmed as causal in humans [pubmed:36905132].
    • Does the literature support anti‑aging or cosmetic efficacy in humans?
    • Not in this packet. These narratives are largely review‑driven or based on preclinical work; primary human outcome trials are not provided here [pubmed:39963574; pubmed:29986520; pubmed:35083444; pubmed:26236730].
    • What do preclinical models report about GHK‑Cu?
    • Reports include attenuation of lung inflammation/fibrosis in silicosis models [pubmed:38879894], mitigation of cigarette smoke–induced emphysema/inflammation [pubmed:35936787], beneficial effects in experimental colitis [pubmed:40672369], and reduced inflammation in zebrafish larvae exposed to CuSO4 or LPS [pubmed:41997403]. These findings are not established human outcomes.
    • Are GHK and GHK‑Cu findings interchangeable across studies?
    • Not necessarily. Copper binding changes peptide interactions; studies distinguish between GHK and GHK‑Cu, and results may differ by form and context [crossref:10.22144/ctu.jen.2018.052; crossref:10.1021/ol0101638; crossref:10.1016/0024-3205(92)90504-i].
    • Are dosing or generalized safety conclusions available?
    • No. The packet does not provide sufficient primary human outcome data to support dosing guidance or generalized safety conclusions.

    References

    • Human/clinical
    • pubmed:36905132 — https://pubmed.ncbi.nlm.nih.gov/36905132/
    • Reviews (context)
    • pubmed:29986520 — https://pubmed.ncbi.nlm.nih.gov/29986520/
    • pubmed:35083444 — https://pubmed.ncbi.nlm.nih.gov/35083444/
    • pubmed:26236730 — https://pubmed.ncbi.nlm.nih.gov/26236730/
    • pubmed:39963574 — https://pubmed.ncbi.nlm.nih.gov/39963574/
    • pubmed:41490200 — https://pubmed.ncbi.nlm.nih.gov/41490200/
    • pubmed:41476424 — https://pubmed.ncbi.nlm.nih.gov/41476424/
    • Preclinical/mechanistic
    • pubmed:38879894 — https://pubmed.ncbi.nlm.nih.gov/38879894/
    • pubmed:35936787 — https://pubmed.ncbi.nlm.nih.gov/35936787/
    • pubmed:41997403 — https://pubmed.ncbi.nlm.nih.gov/41997403/
    • pubmed:40672369 — https://pubmed.ncbi.nlm.nih.gov/40672369/
    • pubmed:40716276 — https://pubmed.ncbi.nlm.nih.gov/40716276/
    • crossref:10.22144/ctu.jen.2018.052 — https://doi.org/10.22144/ctu.jen.2018.052
    • crossref:10.1021/ol0101638 — https://doi.org/10.1021/ol0101638
    • crossref:10.1002/chin.200208210 — https://doi.org/10.1002/chin.200208210
    • crossref:10.1016/0024-3205(92)90504-i — https://doi.org/10.1016/0024-3205(92)90504-i
    • Identity/records (ancillary)
    • pubchem:73587 — https://pubchem.ncbi.nlm.nih.gov/compound/73587
    • patent_search:ghk-cu-copper-tripeptide-1-glycyl-l-histidyl-l-lysine — https://patents.google.com/?q=GHK-Cu+copper+tripeptide-1+glycyl-L-histidyl-L-lysine

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About FOXO4-DRI?

    Research Context

    • The packet contains one human-context study in oncology (senescence-targeting in NSCLC radiotherapy) and multiple reviews/mechanistic papers plus several preclinical studies on FOXO4-DRI or related FOXO4 peptides.
    • Reviews and mechanistic work on cellular senescence and the FOXO4–p53 interaction provide rationale, but they do not substitute for primary human outcome evidence [pubmed:40593617; pubmed:29260442; pubmed:29471104; pubmed:29171222; pubmed:42024235].
    • Claims below are limited to what the supplied citations support and are separated by evidence tier.

    Key Takeaway

    No human trials of FOXO4-DRI are included. One NSCLC radiotherapy study targeted senescence-like fibroblasts (not FOXO4-DRI). Evidence specific to FOXO4-DRI is preclinical or mechanistic.

    Direct Answer

    • Human evidence in this packet pertains to an NSCLC radiotherapy context that targeted senescence-like fibroblasts; FOXO4-DRI was not tested [pubmed:34877934]. Any radiosensitization and reduced radiation-induced pulmonary fibrosis findings are part of that translational program and should not be assumed to be human-only outcomes.
    • For FOXO4-DRI specifically, the packet provides mechanistic and preclinical (animal/in vitro) studies indicating senolytic activity via the FOXO4–p53 axis. These do not establish human efficacy, safety, dosing, delivery, or generalized anti-aging effects.

    Human Evidence (specific to the cited population and endpoints)

    • NSCLC radiotherapy context [pubmed:34877934]
    • Study focus: targeting senescence-like fibroblasts during radiotherapy for non-small cell lung cancer.
    • As reflected in the publication title, the translational program links this approach with tumor radiosensitization and reduced radiation-induced pulmonary fibrosis across its experimental tiers.
    • FOXO4-DRI was not used; conclusions should remain confined to this NSCLC radiotherapy context.

    Review and Mechanistic Context (not human outcome evidence)

    • Mechanistic interface of FOXO4 with p53:
    • The disordered p53 transactivation domain is identified as a target of FOXO4 and of FOXO4-DRI, clarifying a proposed senolytic mechanism; this is not clinical efficacy evidence [pubmed:40593617].
    • Broader senescence and translational framing:
    • Cellular senescence in kidney aging and transplantation [pubmed:29260442; pubmed:29471104].
    • Broader aging and interventional concepts [pubmed:29171222].
    • Conceptual review on retro-inverso peptides targeting the FOXO4–p53 axis in brain aging and cognition [pubmed:42024235].

    Preclinical Evidence (animal/in vitro; model-specific and not established in humans)

    Note: In vitro findings using human-derived cells are preclinical and do not constitute clinical evidence.

    Dermal/keloid

    • FOXO4-DRI induced apoptosis in senescent human keloid fibroblasts in vitro, associated with p53 Ser15 phosphorylation changes and nuclear exclusion [pubmed:39994346].

    Reproductive/Leydig–testis

    • FOXO4-DRI reduced SASP secretion from Leydig cells and improved spermatogenesis in aged mice (in vivo) [pubmed:39025385].
    • FOXO4-DRI alleviated age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice (in vivo) [pubmed:31959736].

    Pulmonary fibrosis

    • A non-DRI FOXO4 peptide (peptide identity not specified as DRI) ameliorated bleomycin-induced pulmonary fibrosis in mice; pathway analysis implicated ECM–receptor interactions (in vivo) [pubmed:35510614].

    Vascular/endothelium

    • FOXO4-DRI regulated endothelial cell senescence via p53 signaling in preclinical endothelial models (model systems; non-clinical) [pubmed:41625068].

    Cartilage/chondrocytes

    • FOXO4-DRI selectively removed senescent cells from in vitro expanded human chondrocytes (in vitro) [crossref:10.3389/fbioe.2021.677576].

    Liver (combination context)

    • Morphological liver changes were reported in experimental animals receiving combined adribastin and FOXO4-DRI (in vivo; descriptive histology). This is not a human safety profile [crossref:10.34680/2076-8052.2023.2(131).216-222].

    Comparative senolytic (context only; not FOXO4-DRI evidence)

    • Ionophore nigericin explored as an alternative senolytic strategy in preclinical models [pubmed:36430735].

    Notes on model scope

    • Several preclinical studies involve FOXO4-DRI specifically (keloid fibroblasts, Leydig/testis, endothelial models, human chondrocytes), while others use a generic/non-DRI FOXO4 peptide (e.g., pulmonary fibrosis). Findings with non-DRI FOXO4 peptides should not be conflated with FOXO4-DRI.

    What Is Not Established by This Packet

    • No direct clinical efficacy or safety data for FOXO4-DRI in humans are provided.
    • Preclinical (animal/in vitro) results should not be treated as established human outcomes.
    • Dosing, delivery method, tolerability, adverse events, and long-term effects in humans are not addressed by the supplied citations.
    • The NSCLC radiotherapy study did not test FOXO4-DRI; its endpoints belong to a broader translational program.
    • Patent listings are included for completeness and are not used as efficacy or safety evidence.

    FAQ

    • Has FOXO4-DRI been tested in humans in this packet?
    • No. The packet provides no human trials of FOXO4-DRI. The one human-context study in NSCLC radiotherapy did not use FOXO4-DRI [pubmed:34877934].
    • What mechanism is proposed for FOXO4-DRI?
    • Mechanistic research identifies the disordered p53 transactivation domain as a target of FOXO4 and FOXO4-DRI, supporting a senolytic hypothesis [pubmed:40593617]. This is not clinical efficacy evidence.
    • Do in vitro results in human cells (e.g., chondrocytes or keloid fibroblasts) count as clinical evidence?
    • No. These are preclinical studies and do not establish outcomes in people [crossref:10.3389/fbioe.2021.677576; pubmed:39994346].
    • Are FOXO4 peptide studies interchangeable with FOXO4-DRI findings?
    • Not necessarily. Some studies use a generic/non-DRI FOXO4 peptide; those results should not be conflated with FOXO4-DRI [pubmed:35510614].
    • Does the packet address dosing, delivery, or tolerability for FOXO4-DRI in humans?
    • No. These aspects are unaddressed in the supplied literature.

    References

    Human/clinical-context

    • [pubmed:34877934]

    Review/mechanistic context

    • [pubmed:40593617]; [pubmed:29260442]; [pubmed:29471104]; [pubmed:29171222]; [pubmed:42024235]

    Preclinical (animal/in vitro)

    • [pubmed:39994346]; [pubmed:39025385]; [pubmed:31959736]; [pubmed:35510614]; [pubmed:41625068]; [crossref:10.3389/fbioe.2021.677576]; [crossref:10.34680/2076-8052.2023.2(131).216-222]; [pubmed:36430735]

    Other sources in packet (not used as efficacy or safety evidence)

    • [patent_search:foxo4-dri-foxo4-dri-peptide-senescence]

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About Follistatin-344?

    Research Context

    Follistatin is a secreted protein that binds and neutralizes activins and related TGF-β family ligands. “Follistatin-344” (FST344) refers to a 344–amino-acid isoform; however, most sources in this packet discuss follistatin generally (and sometimes follistatin-like 3, FSTL3), not isoform-specific clinical outcomes for FST344 [pubmed:9785474; pubmed:15253386; pubmed:37739334]. The packet contains:

    • Human studies in disease-specific, non-interventional contexts (FLT3/ITD acute myeloid leukemia target/biomarker work; circulating hormone profiling in steatotic liver disease; serum follistatin levels in ovarian endometriosis) [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1].
    • Multiple reviews on activin/follistatin biology, signaling, inflammation/immunity, and related systems [pubmed:9785474; pubmed:10077456; pubmed:37739334; pubmed:15253386; pubmed:31322318; pubmed:21353885].
    • Preclinical/mechanistic reports (cancer cachexia pathway mapping; angiogenin-binding) [pubmed:39116208; pubmed:17991437].
    • A nonclinical PK/PD study of an engineered human follistatin variant (not FST344) [crossref:10.1124/jpet.112.0313hia].
    • Forensic/analytical detection of black-market FST344 [pubmed:31758732; crossref:10.1002/dta.2741; crossref:10.1002/dta.2882].

    Isoform specificity clarification: the packet does not present isoform-specific clinical data for FST344; conclusions should not assume equivalence between total follistatin, FST344, and FSTL3.

    Key Takeaway

    The supplied literature offers disease-specific human biomarker/target findings for follistatin but no interventional trials of exogenous FST344. Mechanistic reviews and preclinical studies provide context only and do not establish efficacy, safety, or dosing.

    Direct Answer

    In this packet, direct human evidence related to follistatin is narrow and disease-specific, focusing on target/biomarker work in FLT3/ITD acute myeloid leukemia, circulating hormone measurements in biopsy-proven steatotic liver disease, and serum levels in ovarian endometriosis cohorts [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1]. None of the cited human studies involve interventional administration of exogenous FST344. Mechanistic reviews describe how follistatin modulates activin/TGF-β pathways, providing context but not clinical outcomes [pubmed:9785474; pubmed:10077456; pubmed:37739334; pubmed:15253386; pubmed:31322318; pubmed:21353885]. Preclinical reports map disease-relevant pathways and protein–protein interactions, and analytical studies document detection of black-market FST344; these do not establish clinical efficacy, safety, or dosing for FST344 [pubmed:39116208; pubmed:17991437; crossref:10.1124/jpet.112.0313hia; pubmed:31758732]. Overall, any conclusions should remain anchored to the specific human populations and endpoints studied and should not be generalized.

    Human Evidence (Disease-Specific and Observational)

    • FLT3/ITD acute myeloid leukemia: A study identified follistatin as a potential therapeutic target and biomarker in FLT3/ITD AML [pubmed:32134197]. This work concerns endogenous target/biomarker identification and does not test exogenous FST344 in humans.
    • Steatotic liver disease and steatohepatitis: A multicenter observational study measured circulating hormones, including follistatin, in biopsy-proven steatotic liver disease and steatohepatitis, providing biomarker data within that specific population [pubmed:37757973]. No interventional FST344 administration was involved.
    • Ovarian endometriosis: An observational study reported high serum follistatin levels in women with ovarian endometriosis, consistent with a biomarker association rather than interventional evaluation of FST344 [crossref:10.1016/s1090-798x(10)79409-1].

    Review Context and Mechanistic Background (Not Human Outcomes)

    • Foundational biology and signaling: Reviews summarize follistatin’s binding to activins and other TGF-β family ligands and activin receptor signaling, framing potential mechanisms relevant to diverse tissues [pubmed:9785474; pubmed:15253386].
    • Vascular and metabolic context: Reviews discuss activin/follistatin in atherosclerosis and the roles of follistatin and FSTL3 in metabolic disorders [pubmed:10077456; pubmed:37739334].
    • Immune/reproductive and inflammatory context: Activins, follistatin, and immunoregulation in the epididymis, and broader roles in inflammation and immunity, are discussed in review literature [pubmed:31322318; pubmed:21353885].

    Important clarifications:

    • Isoform specificity: Most reviews address “follistatin” generally; they are not isoform-specific for FST344.
    • Distinct proteins: FSTL3 (follistatin-like 3) is mechanistically related but distinct; findings for FSTL3 are not interchangeable with those for follistatin/FST344, and differential actions between follistatin and FSTL3 have been reported [pubmed:37739334; pubmed:15451564].

    Preclinical and Analytical/Forensic Findings (Nonclinical)

    • Cachexia pathway mapping: A single-nucleus study delineated molecular pathways associated with cancer cachexia–related muscle atrophy; it did not test FST344 or establish direct follistatin effects in humans [pubmed:39116208].
    • Protein–protein interaction: Follistatin was identified as an angiogenin-binding protein, a mechanistic interaction observed outside of human outcome trials [pubmed:17991437].
    • Engineered variant PK/PD (not FST344): A pharmacokinetic/pharmacodynamic study characterized an engineered human follistatin variant in nonclinical settings; it is not FST344 and is not human interventional evidence [crossref:10.1124/jpet.112.0313hia].
    • Forensic detection: Analytical studies detected “black market” FST344 in market/seized samples, indicating detectability but not informing product quality, dosing, safety, efficacy, or prevalence [pubmed:31758732; crossref:10.1002/dta.2741; crossref:10.1002/dta.2882].

    What Is Not Established (Limits of This Packet)

    • No interventional human trials of exogenous FST344 are included in this packet.
    • No randomized clinical trial evidence demonstrates clinical benefit or a defined safety profile for FST344 in broad indications.
    • No dosing, delivery, or regimen guidance is supported by the supplied literature.
    • Preclinical and mechanistic plausibility do not constitute proof of human efficacy or safety.
    • Broad claims (e.g., generalized anti-aging or multi-organ benefits) are unsupported by this packet.
    • Findings for total follistatin or FSTL3 should not be assumed to apply to the specific FST344 isoform without direct evidence.
    • Forensic detection of black-market FST344 does not speak to quality control, safety, dosing, or real-world effectiveness.
    • Conclusions should remain anchored to the specific human populations and endpoints studied [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1].

    FAQ

    • What is Follistatin-344 (FST344)?
    • FST344 refers to a 344–amino-acid isoform of the follistatin protein, which binds activins and related TGF-β ligands. Most literature in this packet addresses follistatin broadly rather than FST344-specific outcomes [pubmed:9785474; pubmed:15253386].
    • Are there human trials testing exogenous FST344?
    • No interventional human studies of exogenous FST344 are included in this packet.
    • What human evidence is available?
    • Observational, disease-specific studies report follistatin as a biomarker/target in FLT3/ITD AML, measure circulating follistatin in steatotic liver disease, and report higher serum levels in ovarian endometriosis; none test exogenous FST344 [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1].
    • Can findings about FSTL3 be applied to FST344?
    • No. FSTL3 is distinct from follistatin and shows differential actions; its findings are not interchangeable with those for follistatin/FST344 [pubmed:15451564; pubmed:37739334].
    • Do black-market detection studies tell us anything about safety or dosing?
    • No. These analytical reports document detection of FST344 in samples but do not inform dosing, safety, efficacy, or prevalence [pubmed:31758732; crossref:10.1002/dta.2741; crossref:10.1002/dta.2882].

    References

    • [pubmed:32134197]
    • [pubmed:37757973]
    • [crossref:10.1016/s1090-798x(10)79409-1]
    • [pubmed:9785474]
    • [pubmed:10077456]
    • [pubmed:37739334]
    • [pubmed:15253386]
    • [pubmed:31322318]
    • [pubmed:21353885]
    • [pubmed:15451564]
    • [pubmed:39116208]
    • [pubmed:17991437]
    • [crossref:10.1124/jpet.112.0313hia]
    • [pubmed:31758732]
    • [crossref:10.1002/dta.2741]
    • [crossref:10.1002/dta.2882]

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About IGF1-LR3?

    This summary draws only from the supplied synthesis packet and keeps human evidence, preclinical results, and mechanistic findings distinct. Claims are limited to what the cited studies support.

    Research Context

    • The packet is driven by animal, in vitro, and tissue-engineering studies; it does not include human clinical outcome trials for LR3 IGF-1 or native IGF-1. The packet advises against broad human-efficacy framing.
    • Several findings concern native IGF-1 rather than LR3 IGF-1; results are context-dependent across analogue, species, age, route, and delivery format. Findings for IGF-1 and LR3 should not be treated as interchangeable.

    Key Takeaway

    Published IGF-1 LR3 evidence is primarily preclinical and model-specific. Some studies report biomarker or tissue changes, but there are no human efficacy or safety outcomes in this packet, and translational relevance remains uncertain.

    Direct Answer

    • Direct human efficacy or safety evidence for IGF-1 LR3 is absent in this packet.
    • Preclinical studies report heterogeneous, model-specific effects for LR3 IGF-1 and/or native IGF-1 across growth, metabolism, neuropathology markers, and nerve repair, with outcomes varying by analogue, species, age, route, and delivery construct.
    • Mechanistic and structural work supports biological plausibility but does not establish clinical utility. Dosing or safety conclusions for humans are not supported by the packet.

    Evidence by Category

    Human evidence

    • No controlled human clinical trials or direct human-outcome studies for LR3 IGF-1 are included in the packet.
    • The packet does not support dosing or generalized safety conclusions for humans.

    Animal and tissue-engineering studies (preclinical)

    • Growth and gut proliferation (rats; LR3 IGF-1 and/or native IGF-1): Systemic infusion of IGF-1 or LR3 IGF-1 stimulated visceral organ growth and gut tissue proliferation in suckling rats [pubmed:9124573]. These neonatal rat findings are not generalizable to humans.
    • Fetal growth (sheep; native IGF-1 vs LR3 IGF-1):
    • Native IGF-1 infusion increased organ growth in fetal sheep without evidence of increased placental/fetal nutrient transfer [pubmed:33427051]. This prenatal agricultural model has uncertain relevance to adult human outcomes.
    • LR3 IGF-1 did not promote growth in late-gestation growth-restricted fetal sheep [pubmed:39679943]. Model- and condition-specific context limits extrapolation.
    • Islet function (sheep; native IGF-1): A 1-week native IGF-1 infusion in late-gestation fetal sheep reduced glucose-stimulated insulin secretion due to an intrinsic islet defect in that model [pubmed:33938236]; implications beyond this prenatal context are unknown.
    • Neuropathology marker vs function (mice; LR3 IGF-1, intranasal): Intranasal LR3 IGF-1 promoted amyloid plaque remodeling in male 5XFAD mice but did not preserve cognitive function [pubmed:39610283]. Biomarker changes did not translate to behavioral benefit in this model.
    • Peripheral nerve repair (rats; LR3 IGF-1, localized construct): A decellularized Alstroemeria stem-based conduit with GelMA and controlled LR3 IGF-1 release reported enhanced sciatic nerve regeneration in a rat model; effects pertain to this localized tissue-engineering context [pubmed:41015370] and should not be extrapolated to systemic delivery.
    • Protein metabolism (cattle; LR3 IGF-1): LR3 IGF-1 affected protein metabolism in beef heifers [pubmed:10370861]; this agricultural model has uncertain human relevance.
    • Route- and age-dependent intestinal effects (rats; LR3 IGF-1 and/or native IGF-1):
    • LR3 IGF-1 showed preferential intestinal delivery compared with native IGF-1 in preweaning and adult rats [pubmed:12697696]. This rat finding does not establish human oral bioavailability.
    • Systemic, but not orogastric, delivery of IGF-1 or LR3 IGF-1 increased intestinal disaccharidase activity in suckling rats [pubmed:9803447]. Lack of effect via the orogastric route in this model should not be overinterpreted for humans.
    • Reproductive endpoints (rats; LR3 IGF-1): Older reports describe enhanced superovulatory response with LR3 IGF-1 infusion; methodological detail is limited [crossref:10.1016/S0015-0282(97)84896-0; crossref:10.1016/S0015-0282(97)90811-6]. These findings should be viewed as preliminary.

    Applied/analytical and production context

    • Recombinant expression approaches (including Pichia pastoris fusions) and physicochemical characterization of LR3 IGF-1 inclusion bodies are reported [crossref:10.1007/s00253-023-12606-0; crossref:10.1021/bp010058x].
    • Detection of His-tagged LR3 IGF-1 in an unregulated product is described in an analytical report; this is descriptive and nonclinical [crossref:10.1016/j.ghir.2010.07.001].

    Mechanistic and in vitro evidence

    • Structure: Solution NMR characterized the structure and backbone dynamics of LR3 IGF-1 [pubmed:10744677].
    • Signaling modulation (cell system–specific): N-linked glycosylation in Chinese hamster ovary cells was critical for IGF-1 signaling in that system; this study does not distinguish LR3-specific effects [pubmed:36499281].
    • Hematopoietic cell biology: IGF-1 and IGF-binding proteins were involved in proliferation and differentiation of murine bone marrow–derived macrophage precursors in vitro/ex vivo [pubmed:9867252].

    Gaps and limits

    • No direct human efficacy, safety, dose–response, or durability data for LR3 IGF-1 are included in the packet.
    • Findings differ by analogue (native IGF-1 vs LR3 IGF-1), species, age, route, and delivery construct; results from one context do not generalize across models.
    • Rat intestinal-delivery findings should not be taken as evidence of human oral bioavailability [pubmed:12697696; pubmed:9803447].
    • Changes in disease biomarkers without corresponding functional benefit (e.g., amyloid plaque remodeling without cognitive preservation) leave clinical relevance uncertain [pubmed:39610283].
    • Localized tissue-engineering results (e.g., nerve conduit delivery) should not be extrapolated to systemic administration or different indications [pubmed:41015370].
    • The product-detection report is descriptive and does not evaluate safety, efficacy, or manufacturing quality [crossref:10.1016/j.ghir.2010.07.001].

    FAQ

    • Is there human clinical evidence for IGF-1 LR3 in this packet?
    • No. The packet includes no controlled human clinical trials or direct human-outcome studies for LR3 IGF-1.
    • Does IGF-1 LR3 improve cognition in Alzheimer’s-model mice?
    • In male 5XFAD mice, intranasal LR3 IGF-1 remodeled amyloid plaques but did not preserve cognitive function [pubmed:39610283].
    • Do rat intestinal-delivery studies imply oral bioavailability in humans?
    • No. Preferential intestinal delivery and disaccharidase findings are in rats and do not establish human oral bioavailability [pubmed:12697696; pubmed:9803447].
    • Are IGF-1 and LR3 IGF-1 findings interchangeable?
    • No. Effects vary by analogue, species, age, route, and delivery construct; results should not be conflated.
    • What do prenatal or agricultural models (fetal sheep, heifers) tell us about humans?
    • They inform biology in those contexts but have uncertain relevance to adult human outcomes [pubmed:33427051; pubmed:33938236; pubmed:10370861].

    References

    • IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. https://pubmed.ncbi.nlm.nih.gov/39679943/
    • Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. https://pubmed.ncbi.nlm.nih.gov/39610283/
    • Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration. https://pubmed.ncbi.nlm.nih.gov/41015370/
    • Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers. https://pubmed.ncbi.nlm.nih.gov/10370861/
    • IGF-1 infusion to fetal sheep increases organ growth but not by stimulating nutrient transfer to the fetus. https://pubmed.ncbi.nlm.nih.gov/33427051/
    • Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep is due to an intrinsic islet defect. https://pubmed.ncbi.nlm.nih.gov/33938236/
    • Preferential intestinal delivery of long[Arg3] insulin-like growth factor (LR3IGF-I) over IGF-I in preweaning and adult rats. https://pubmed.ncbi.nlm.nih.gov/12697696/
    • Systemically but not orogastrically delivered insulin-like growth factor (IGF)-I and long [Arg3]IGF-I stimulates intestinal disaccharidase activity in two age groups of suckling rats. https://pubmed.ncbi.nlm.nih.gov/9803447/
    • N-Linked Glycosylation in Chinese Hamster Ovary Cells Is Critical for Insulin-like Growth Factor 1 Signaling. https://pubmed.ncbi.nlm.nih.gov/36499281/
    • Involvement of insulin-like growth factor-1 and its binding proteins in proliferation and differentiation of murine bone marrow-derived macrophage precursors. https://pubmed.ncbi.nlm.nih.gov/9867252/
    • Systemic infusion of IGF-I or LR(3)IGF-I stimulates visceral organ growth and proliferation of gut tissues in suckling rats. https://pubmed.ncbi.nlm.nih.gov/9124573/
    • Solution structure and backbone dynamics of long-[Arg(3)]insulin-like growth factor-I. https://pubmed.ncbi.nlm.nih.gov/10744677/
    • In Vivo Infusion With IGF-I Analogue, Long Arg3-Insulin-Like Growth Factor-I (LR3-IGF-I) Enhances Superovulatory Response in Rats. https://doi.org/10.1016/s0015-0282(97)84896-0
    • O-179 In vivo infusion with IGF-I analogue, long Arg3-insulin-like growth factor-I (LR3-IGF-I) enhances superovulatory response in rats. https://doi.org/10.1016/S0015-0282(97)90811-6
    • Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. https://doi.org/10.1007/s00253-023-12606-0
    • Physicochemical Characteristics of LR3-IGF1 Protein Inclusion Bodies: Electrophoretic Mobility Studies. https://doi.org/10.1021/bp010058x
    • Detection of His-tagged Long-R3-IGF-I in a black market product. https://doi.org/10.1016/j.ghir.2010.07.001

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About AOD-9604?

    Research Context

    The packet includes: (a) limited direct human data indicating favorable safety/tolerability for AOD-9604 in a phase II clinical setting and FDA PCAC materials outlining clinical/regulatory context [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891; fda:pcac-aod-9604-183584]; (b) review literature on therapeutic peptides and obesity pharmacotherapy that provides field context but not AOD-9604–specific clinical outcomes [pubmed:41490200; pubmed:16931496; pubmed:17971763; pubmed:22435392; pubmed:16625817; pubmed:15134286]; and (c) preclinical studies (animal/in vitro) plus analytical/anti-doping detection literature for AOD-9604 and related growth-hormone fragments [pubmed:11673763; pubmed:11713213; pubmed:11146367; pubmed:25208511; pubmed:24124033; pubmed:26213263].

    Key Takeaway

    In this packet, direct human evidence for AOD-9604 is limited to a phase II safety/tolerability signal; the provided citations do not establish human efficacy outcomes.

    Direct Answer

    • A phase II clinical study reported favorable safety and tolerability for AOD-9604; conclusions should remain limited to the specific population and endpoints studied (safety/tolerability-focused) [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891].
    • Reviews frame the broader peptide and obesity-therapy landscape but are not substitutes for primary human outcome evidence and are not specific proof of AOD-9604 clinical benefit [pubmed:41490200; pubmed:16931496; pubmed:17971763; pubmed:22435392; pubmed:16625817; pubmed:15134286].
    • Preclinical mouse and in vitro studies report metabolic/lipolytic or characterization findings; these do not establish human outcomes [pubmed:11673763; pubmed:11713213; pubmed:11146367; pubmed:25208511]. In some rodent work, related GH fragments were studied that may not be identical to AOD-9604.
    • Analytical studies address detection and assay interference; they inform testing context, not clinical efficacy or safety [pubmed:24124033; pubmed:26213263; pubmed:25208511].

    Direct human evidence

    • A phase II clinical trial in an obesity-related context reported a favorable safety/tolerability signal for AOD-9604; the evaluated endpoints focused on safety/tolerability rather than efficacy [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891].
    • Guardrail: Do not infer efficacy or generalized safety beyond the specific population and endpoints evaluated in the cited human study and FDA PCAC review materials [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891; fda:pcac-aod-9604-183584].

    Review literature (field context; not proof of outcomes)

    • Reviews cover therapeutic peptides (including an orthopaedics-focused overview) and obesity pharmacotherapy. These provide mechanistic/translational context but do not establish AOD-9604 clinical outcomes [pubmed:41490200; pubmed:16931496; pubmed:17971763; pubmed:22435392; pubmed:16625817].
    • Classification note: pubmed:15134286 is treated here as contextual/non-primary; it should not be used to claim human outcomes for AOD-9604 [pubmed:15134286].

    Preclinical and mechanistic evidence

    • Sequence/characterization: AOD-9604 corresponds to the C-terminal fragment of human growth hormone (amino acids 177–191) with an additional N-terminal tyrosine [pubmed:25208511; pubmed:11146367].
    • Animal/in vitro findings (model scope reflected by titles):
    • Obese mice: chronic treatment with human GH or a modified C-terminal fragment increased fat oxidation and reduced weight [pubmed:11673763].
    • Obese and β3-adrenergic receptor knockout mice: human GH and the lipolytic fragment AOD-9604 affected lipid metabolism after chronic treatment [pubmed:11713213].
    • In vitro/biochemical: metabolic studies of a synthetic lipolytic domain (AOD-9604) [pubmed:11146367].
    • In vitro/analytical: detection and in vitro metabolism of AOD-9604 [pubmed:25208511].
    • Translation caveat: Some rodent data involve fragments related to, but not necessarily identical with, AOD-9604. These results are hypothesis-generating and should not be presented as established human outcomes [pubmed:11673763; pubmed:11713213; pubmed:11146367; pubmed:25208511].

    Analytical detection and anti-doping context (not clinical outcomes)

    • AOD-9604 does not influence the WADA hGH isoform immunoassay; this finding is assay-specific and should not be generalized to all GH-related assays [pubmed:24124033].
    • Mass-spectrometry reviews and detection/metabolism studies describe analytical identification of peptides/AOD-9604; these do not inform clinical benefit [pubmed:26213263; pubmed:25208511].

    What is not established (limitations from the packet)

    • Broad claims of clinical efficacy beyond the specific human endpoints studied are not supported by the provided citations in this packet [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891; fda:pcac-aod-9604-183584].
    • Dosing guidance and generalized safety outside the studied setting are not justified by the packet [fda:pcac-aod-9604-183584; crossref:10.2165/00128413-200313770-00018].
    • Animal/in vitro findings should not be reframed as proven clinical efficacy; mechanistic plausibility alone does not establish clinical utility [pubmed:11673763; pubmed:11713213; pubmed:11146367; pubmed:25208511].

    FAQ

    • What human outcomes are supported for AOD-9604?
    • In this packet, a phase II study reported favorable safety/tolerability; no human efficacy outcomes are established in the provided citations [crossref:10.2165/00128413-200313770-00018; fda:pcac-aod-9604-183891; fda:pcac-aod-9604-183584].
    • Does AOD-9604 reduce fat or weight in humans?
    • Not established in this packet. Rodent studies reported metabolic/weight effects, but these are not evidence of human outcomes [pubmed:11673763; pubmed:11713213].
    • What exactly is AOD-9604?
    • A peptide corresponding to hGH residues 177–191 with an added N-terminal tyrosine, characterized in preclinical/analytical work [pubmed:25208511; pubmed:11146367].
    • Does AOD-9604 interfere with growth hormone anti-doping tests?
    • One study found it does not influence the WADA hGH isoform immunoassay; this is assay-specific and does not generalize to all assays. Detection by mass spectrometry is described in analytical literature [pubmed:24124033; pubmed:26213263; pubmed:25208511].
    • Are there dosing or broad safety recommendations?
    • No. The packet does not justify dosing guidance or generalized safety beyond the cited human study context [fda:pcac-aod-9604-183584; crossref:10.2165/00128413-200313770-00018].

    References

    • [crossref:10.2165/00128413-200313770-00018] The anti-obesity drug AOD-9604* has demonstrated favourable safety and tolerability in a phase II clinical trial. https://doi.org/10.2165/00128413-200313770-00018
    • [fda:pcac-aod-9604-183891] FDA PCAC meeting material: AOD-9604 clinical and regulatory context. https://www.fda.gov/media/183891/download
    • [fda:pcac-aod-9604-183584] FDA PCAC support document: AOD-9604 literature and clinical-study review. https://www.fda.gov/media/183584/download
    • [pubmed:41490200] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. https://pubmed.ncbi.nlm.nih.gov/41490200/
    • [pubmed:15134286] AOD-9604 Metabolic. https://pubmed.ncbi.nlm.nih.gov/15134286/
    • [pubmed:25208511] Detection and in vitro metabolism of AOD9604. https://pubmed.ncbi.nlm.nih.gov/25208511/
    • [pubmed:26213263] Human sports drug testing by mass spectrometry. https://pubmed.ncbi.nlm.nih.gov/26213263/
    • [pubmed:11713213] The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. https://pubmed.ncbi.nlm.nih.gov/11713213/
    • [pubmed:16931496] Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. https://pubmed.ncbi.nlm.nih.gov/16931496/
    • [pubmed:17971763] [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. https://pubmed.ncbi.nlm.nih.gov/17971763/
    • [pubmed:11673763] Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. https://pubmed.ncbi.nlm.nih.gov/11673763/
    • [pubmed:22435392] Current updates in the medical management of obesity. https://pubmed.ncbi.nlm.nih.gov/22435392/
    • [pubmed:16625817] Obesity drugs in clinical development. https://pubmed.ncbi.nlm.nih.gov/16625817/
    • [pubmed:11146367] Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. https://pubmed.ncbi.nlm.nih.gov/11146367/
    • [pubmed:24124033] AOD-9604 does not influence the WADA hGH isoform immunoassay. https://pubmed.ncbi.nlm.nih.gov/24124033/

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About Semaglutide?

    Research Context

    The synthesis packet contains 12 PubMed-indexed sources: eight primary human studies and four reviews; no preclinical sources. Conclusions should remain anchored to the specific populations, endpoints, and formulations explicitly studied. Review literature can frame context but does not substitute for primary human outcome data.

    Direct Answer

    Published human randomized trials in this packet most robustly report weight-management outcomes primarily in adults with overweight or obesity without diabetes, using both subcutaneous and oral formulations [pubmed:35015037][pubmed:37385278][pubmed:38330988]. Additional human research addresses functional capacity (walking outcomes) in people with symptomatic peripheral artery disease and type 2 diabetes [pubmed:40169145]. Cardiovascular outcomes and metabolic dysfunction–associated steatohepatitis (MASH) are represented here only by trial design/baseline publications, without reported outcomes [pubmed:36945734][pubmed:39412509]. Systematic reviews synthesize efficacy in obesity without diabetes; a safety-focused review addresses semaglutide more broadly and should not be over-narrowed to obesity-only contexts [pubmed:36578889][pubmed:38679221][pubmed:34942372][pubmed:34305810].

    Human Clinical Evidence

    • Weight management in adults (primarily without diabetes)
    • STEP 8: Weekly subcutaneous semaglutide versus daily liraglutide; primary outcomes centered on body-weight change in adults with overweight or obesity without diabetes [pubmed:35015037].
    • OASIS 1: Oral semaglutide 50 mg once daily versus placebo; weight outcomes in adults with overweight or obesity (the title does not specify diabetes status) [pubmed:37385278].
    • STEP 7: Once-weekly semaglutide 2.4 mg versus placebo; weight outcomes in a predominantly East Asian population with overweight or obesity [pubmed:38330988].
    • Functional capacity in peripheral artery disease with type 2 diabetes
    • STRIDE (phase 3b): Double-blind, randomized, placebo-controlled trial evaluating walking capacity endpoints in people with symptomatic peripheral artery disease and type 2 diabetes [pubmed:40169145].
    • Cardiovascular outcomes (design/baseline only in this packet)
    • SOUL: Design and baseline characteristics for a randomized cardiovascular outcomes trial of oral semaglutide in people with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease; no outcomes are reported in the materials provided here [pubmed:36945734].
    • MASH (design/baseline only in this packet)
    • ESSENCE (phase 3): Baseline characteristics and trial design evaluating semaglutide 2.4 mg in participants with MASH; no outcomes are reported in the materials provided here [pubmed:39412509].
    • Comparator and combination contexts (do not imply monotherapy outcomes)
    • Tirzepatide comparator trial (phase 1): Multicenter, randomized, double-blind study comparing tirzepatide with placebo or semaglutide on islet function and insulin sensitivity in adults with type 2 diabetes; this context does not establish semaglutide monotherapy efficacy beyond its role as a comparator [pubmed:35468322].
    • Cagrilintide–semaglutide combination: Study in adults with overweight or obesity and type 2 diabetes; as a combination therapy, it does not isolate semaglutide monotherapy effects [pubmed:40544432].

    Outcome evidence is strongest for weight-management trials primarily in adults without diabetes. Cardiovascular and MASH questions are represented here by design/baseline papers only and should not be interpreted as established clinical outcomes within this packet.

    Review Literature

    • Systematic review and meta-analysis on efficacy and safety for weight loss in obesity without diabetes [pubmed:36578889].
    • Systematic review and meta-analysis on long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes across randomized controlled trials [pubmed:38679221].
    • Review on semaglutide for the treatment of obesity [pubmed:34942372].
    • Safety-focused review addressing semaglutide broadly (not limited to obesity without diabetes) [pubmed:34305810].

    These reviews contextualize mechanisms, efficacy, and safety but remain limited by the included primary RCTs and do not extend findings to unstudied populations, endpoints, or formulations beyond those tested.

    Preclinical and Mechanistic Evidence

    • No preclinical or purely mechanistic sources are included in the packet.

    What Is Not Established

    • Cardiovascular outcomes and MASH efficacy: Only trial designs/baseline characteristics are included (SOUL, ESSENCE); no outcome data are provided here and efficacy should not be inferred.
    • Generalized dosing and safety extrapolation beyond the studied contexts.
    • Anti-aging or broad peptide claims unsupported by direct human outcomes in this packet.
    • Cross-formulation or cross-population generalizations not tested in the cited studies.

    References

    • [pubmed:35015037] Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/35015037/
    • [pubmed:37385278] Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. https://pubmed.ncbi.nlm.nih.gov/37385278/
    • [pubmed:38330988] Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. https://pubmed.ncbi.nlm.nih.gov/38330988/
    • [pubmed:40169145] Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/40169145/
    • [pubmed:36945734] Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. https://pubmed.ncbi.nlm.nih.gov/36945734/
    • [pubmed:39412509] Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. https://pubmed.ncbi.nlm.nih.gov/39412509/
    • [pubmed:35468322] Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. https://pubmed.ncbi.nlm.nih.gov/35468322/
    • [pubmed:40544432] Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/40544432/
    • [pubmed:36578889] Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. https://pubmed.ncbi.nlm.nih.gov/36578889/
    • [pubmed:38679221] Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. https://pubmed.ncbi.nlm.nih.gov/38679221/
    • [pubmed:34942372] Semaglutide for the treatment of obesity. https://pubmed.ncbi.nlm.nih.gov/34942372/
    • [pubmed:34305810] Safety of Semaglutide. https://pubmed.ncbi.nlm.nih.gov/34305810/

    Research-use-only catalog access

    KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.

    Access catalog path
    Browse technical product pages

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About Tirzepatide?

    Research Context

    The supplied synthesis packet includes twelve human clinical sources, zero review sources, and zero preclinical sources. The citations therefore represent human clinical studies but are not uniformly interventional outcome reports; study designs vary by citation. The packet explicitly cautions that conclusions should remain anchored to the specific populations, endpoints, and disease contexts studied in those human studies [pubmed:38078870, pubmed:35658024, pubmed:34170647, pubmed:39536238, pubmed:37758044].

    The packet assigns high confidence to the presence of direct human evidence and medium confidence to any generalization across populations or endpoints [pubmed:38078870, pubmed:35658024, pubmed:34170647, pubmed:39536238, pubmed:37758044]. It contains no review or preclinical sources.

    Direct Answer

    Published research on tirzepatide in this packet consists of human clinical studies across obesity, type 2 diabetes, and select comorbid populations (e.g., obstructive sleep apnea with obesity, heart failure with preserved ejection fraction with obesity, and metabolic dysfunction–associated steatohepatitis). The strongest conclusions should remain tied to the specific populations and endpoints of each study. Notably, at least one cardiovascular citation (SURPASS-CVOT design/baseline characteristics) is a design/baseline paper rather than an outcomes report [pubmed:37758044]. No dosing guidance, broad safety generalizations, or mechanistic claims are supported by this packet alone.

    Human Clinical Evidence by Topic (based on citation titles)

    • Obesity and weight maintenance:
    • Continued treatment for maintenance of weight reduction in adults with obesity (SURMOUNT-4) [pubmed:38078870].
    • Tirzepatide once weekly for the treatment of obesity [pubmed:35658024].
    • Obesity treatment in people with type 2 diabetes (SURMOUNT-2) [pubmed:37385275].
    • Obesity treatment and diabetes prevention [pubmed:39536238].
    • Type 2 diabetes and cardiovascular context:
    • Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes [pubmed:34170647].
    • SURPASS-CVOT design and baseline characteristics comparing tirzepatide and dulaglutide for major adverse cardiovascular events; this is a design/baseline report and does not provide outcomes [pubmed:37758044].
    • Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes [pubmed:41406444].
    • Obesity-related comorbidities:
    • Tirzepatide for obstructive sleep apnea and obesity [pubmed:38912654].
    • Tirzepatide for heart failure with preserved ejection fraction and obesity [pubmed:39555826].
    • Metabolic liver disease:
    • Tirzepatide for metabolic dysfunction–associated steatohepatitis with liver fibrosis [pubmed:38856224].
    • Comparative pharmacotherapy for overweight or obesity:
    • Semaglutide versus tirzepatide for weight loss in adults with overweight or obesity [pubmed:38976257, pubmed:40353578].

    Study Design Notes and Limits

    • Study designs vary across citations (e.g., randomized trials, design/baseline reports, and other human clinical study types). Conclusions should be interpreted within each study’s design constraints; the packet does not specify uniform RCT outcomes for all entries [pubmed:37758044].
    • The SURPASS-CVOT citation provided is a design/baseline characteristics paper and should not be interpreted as reporting cardiovascular outcomes [pubmed:37758044].
    • Several citations focus on comorbid subpopulations (e.g., type 2 diabetes with obesity, heart failure with preserved ejection fraction with obesity, obstructive sleep apnea with obesity), which limits generalizability to broader populations.
    • The packet does not reproduce quantitative efficacy or safety data. Absence of such data here does not imply absence in the primary publications; readers should consult the cited papers for detailed results and safety findings.

    What Is Not Established by This Packet

    • Dosing, comprehensive safety profiles, and off-label extrapolation are not established by the supplied materials and remain incompletely addressed.
    • Anti-aging or broad metabolic enhancement claims are not supported.
    • Mechanistic plausibility alone does not establish clinical utility; mechanistic or animal-based inferences are outside the scope of this packet.
    • Broad generalization beyond the studied populations and endpoints is not warranted.

    Evidence Not Included in the Packet

    • Review literature: none included.
    • Preclinical/mechanistic studies: none included.

    References

    • [pubmed:38078870] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/38078870/
    • [pubmed:35658024] Tirzepatide Once Weekly for the Treatment of Obesity. https://pubmed.ncbi.nlm.nih.gov/35658024/
    • [pubmed:34170647] Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/34170647/
    • [pubmed:39536238] Tirzepatide for Obesity Treatment and Diabetes Prevention. https://pubmed.ncbi.nlm.nih.gov/39536238/
    • [pubmed:37758044] Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. https://pubmed.ncbi.nlm.nih.gov/37758044/
    • [pubmed:38912654] Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. https://pubmed.ncbi.nlm.nih.gov/38912654/
    • [pubmed:39555826] Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. https://pubmed.ncbi.nlm.nih.gov/39555826/
    • [pubmed:37385275] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. https://pubmed.ncbi.nlm.nih.gov/37385275/
    • [pubmed:38976257] Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. https://pubmed.ncbi.nlm.nih.gov/38976257/
    • [pubmed:40353578] Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. https://pubmed.ncbi.nlm.nih.gov/40353578/
    • [pubmed:38856224] Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. https://pubmed.ncbi.nlm.nih.gov/38856224/
    • [pubmed:41406444] Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/41406444/

    Research-use-only catalog access

    KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.

    Access catalog path
    Browse technical product pages

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About Retatrutide?

    Research Context

    Retatrutide (LY3437943) is a triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon receptors [pubmed:37366315][pubmed:37385280][pubmed:38858523][pubmed:41090431]. The literature base includes: (1) primary human phase 2 trials, (2) review articles offering class-level and mechanistic context, and (3) translational/preclinical work spanning discovery to early clinical proof-of-concept. This article separates those layers and anchors conclusions to the human data.

    Direct Answer

    Direct human evidence for retatrutide comes from randomized phase 2 trials in adults with obesity, in people with type 2 diabetes, and in metabolic dysfunction-associated steatotic liver disease (MASLD) [pubmed:37366315][pubmed:37385280][pubmed:38858523]. Registrational TRIUMPH trial designs for obesity, obstructive sleep apnea (OSA), and knee osteoarthritis are published and ongoing, with no outcomes reported yet [pubmed:41090431]. Review literature provides mechanistic and class-level context for incretin-based therapies but does not substitute for retatrutide-specific outcome data [pubmed:38843460][pubmed:38302593][pubmed:39952695][pubmed:38687506][pubmed:40563436][pubmed:39761578][pubmed:38511400]. Class-level GLP-1 receptor agonist cardiorenal benefits have not been demonstrated for retatrutide.

    Direct Human Evidence

    • Evidence scope and populations. Randomized phase 2 trials have evaluated retatrutide in: adults with obesity [pubmed:37366315]; people with type 2 diabetes [pubmed:37385280]; and individuals with MASLD [pubmed:38858523].
    • Endpoints studied. The obesity trial assessed body-weight outcomes [pubmed:37366315]. The type 2 diabetes trial (double-blind, placebo- and active-controlled) focused on glycemic control [pubmed:37385280]. The MASLD trial examined hepatic outcomes (e.g., imaging/biomarker-based) [pubmed:38858523].
    • Ongoing registrational program. TRIUMPH registrational trial designs for obesity, OSA, and knee osteoarthritis are published, but outcomes have not been reported; these designs do not imply established efficacy for OSA or knee osteoarthritis [pubmed:41090431].

    Taken together, the strongest conclusions should remain anchored to the studied populations, endpoints, and disease contexts from these phase 2 trials [pubmed:37366315][pubmed:37385280][pubmed:38858523][pubmed:41090431].

    Review Literature and Translational Context

    Review articles frame the broader incretin landscape, including GLP-1 receptor agonist development for type 2 diabetes and obesity and established cardiorenal benefits in select populations for some GLP-1 agents; these class-level findings have not been demonstrated for retatrutide [pubmed:38843460]. Additional reviews describe the obesity pharmacotherapy pipeline [pubmed:38302593][pubmed:39952695], interactions between incretin-based therapy and resistance exercise on body composition [pubmed:38687506], and position retatrutide within the evolving treatment landscape [pubmed:40563436]. Systematic review data on GLP-1 receptor agonists for weight management in adults without diabetes and foundational insights into gut hormone biology add further context, without serving as retatrutide-specific outcome evidence [pubmed:39761578][pubmed:38511400].

    Review literature can inform mechanisms and translational plausibility but does not replace primary human outcomes for retatrutide itself [pubmed:38843460][pubmed:38302593][pubmed:39952695][pubmed:38687506][pubmed:40563436].

    Preclinical and Mechanistic Evidence

    A translational report describes the discovery of LY3437943 through early clinical proof-of-concept, providing mechanistic rationale for targeting GIP, GLP-1, and glucagon receptors [pubmed:35985340]. While informative, this discovery-to-PoC continuum does not establish definitive clinical outcomes beyond the dedicated phase 2 trials, and animal or in vitro signals should not be presented as established human effects [pubmed:35985340].

    What Is Not Established

    • Dosing specifics, comprehensive safety profiles, and long-term outcomes remain incompletely addressed in the available literature.
    • Class-level GLP-1 receptor agonist cardiorenal benefits should not be generalized to retatrutide absent direct evidence [pubmed:38843460].
    • TRIUMPH registrational trials for obesity, OSA, and knee osteoarthritis are ongoing; no outcomes have been published, and efficacy in OSA or knee osteoarthritis should not be inferred from trial designs [pubmed:41090431].
    • Translational and preclinical findings, including early PoC signals, are not substitutes for established clinical outcomes [pubmed:35985340].

    References

    • [pubmed:37366315] Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.
    • [pubmed:37385280] Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial.
    • [pubmed:38858523] Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial.
    • [pubmed:41090431] Retatrutide for obesity, obstructive sleep apnea, and knee osteoarthritis: TRIUMPH registrational trial designs.
    • [pubmed:38843460] Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
    • [pubmed:38302593] What is the pipeline for future medications for obesity?
    • [pubmed:39952695] Emerging pharmacotherapies for obesity: A systematic review.
    • [pubmed:38687506] Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
    • [pubmed:40563436] Retatrutide—A Game Changer in Obesity Pharmacotherapy. (review context only)
    • [pubmed:39761578] Efficacy and Safety of GLP-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review.
    • [pubmed:38511400] Gut hormones and appetite regulation.
    • [pubmed:35985340] LY3437943, a novel triple GCG, GIP, and GLP-1 receptor agonist: From discovery to early clinical proof of concept.

    Research-use-only catalog access

    KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.

    Access catalog path
    Browse technical product pages

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About MOTS-C?

    Research Context

    MOTS-c is a mitochondrial-derived peptide encoded by the mitochondrial genome. The supplied synthesis packet includes 10 PubMed-indexed citations (one review). Packet-level notes emphasize that the evidence base is driven mainly by preclinical/mechanistic work. While the packet classifies a subset of citations as “clinical,” it provides little or no study-design or endpoint detail. Accordingly, we separate packet-classified human signals from review context and preclinical/mechanistic findings and avoid extrapolating beyond the specific disease contexts suggested by titles. Where titles are clearly mechanistic, we treat those items as preclinical even if packet classifications appear inconsistent.

    Direct Answer

    Based on this packet, MOTS-c research is predominantly preclinical/mechanistic. The packet classifies a limited set of citations as clinical signals, but without study-design or endpoint details, any conclusions must remain narrowly constrained to the populations and outcomes indicated by their titles. The strongest supported conclusions should stay anchored to the studied human population, endpoint, and disease context. The packet does not establish dosing, safety profiles, generalized anti-aging effects, or broad clinical utility.

    Citations the packet classifies as clinical (designs not provided)

    The packet flags the following as clinical. Because study designs, populations, and endpoints are not provided here, interpretation should remain tightly limited to the contexts suggested by the titles.

    • pubmed:25738459 — Title indicates promotion of metabolic homeostasis and reduction of obesity and insulin resistance. Packet-classified as clinical; specific design, population, and endpoints are not provided. Do not generalize beyond the metabolic contexts in the title.
    • pubmed:34798268 — Title indicates relief of hyperglycemia and insulin resistance in gestational diabetes mellitus. Packet-classified as clinical; specific to GDM. Designs and endpoints are not provided and should not be generalized outside this context.
    • pubmed:33554779 — Title indicates reductions in myostatin and muscle atrophy signaling. Packet-classified as clinical; the title emphasizes signaling changes rather than clinical function or outcomes. Do not imply clinical efficacy for muscle atrophy without endpoints.

    Preclinical and mechanistic evidence from packeted primary articles

    In the absence of detailed methods within the packet, the following are treated as preclinical/mechanistic (species and endpoints not specified here):

    • pubmed:29983246 — Title indicates that a mitochondrial-encoded peptide translocates to the nucleus to regulate nuclear gene expression under metabolic stress. Mechanistic.
    • pubmed:39321430 — Title indicates suppression of ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination. Mechanistic/oncology pathway; not human clinical efficacy.
    • pubmed:38790718 — Title indicates alleviation of radiation pneumonitis via an Nrf2-dependent mechanism. Preclinical/mechanistic.
    • pubmed:37788894 — Title indicates mitochondrial remodelling contributing to an antiviral role during HBV infection. Preclinical/mechanistic.
    • pubmed:37290680 — Title indicates suppression of ferroptosis and alleviation of acute lung injury after myocardial ischemia–reperfusion via PPARγ signaling. Preclinical/mechanistic.
    • pubmed:38206815 — Title indicates interaction with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. Preclinical/mechanistic.

    Review Context

    • A narrative review discusses MOTS-c in diabetes and aging-related diseases [pubmed:36824008]. This is background context and does not constitute primary clinical efficacy evidence within this packet.

    What Is Not Established by This Packet

    • Generalized anti-aging efficacy claims are not supported.
    • Dosing and safety conclusions are not established here.
    • Mechanistic plausibility does not establish clinical utility; direct human studies with specified endpoints and populations would be needed.
    • Packet classifications may be inconsistent with article titles; consult original studies to verify human-study status and endpoints before drawing clinical inferences.

    References

    • The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. PubMed: https://pubmed.ncbi.nlm.nih.gov/25738459/
    • The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. PubMed: https://pubmed.ncbi.nlm.nih.gov/34798268/
    • Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination. PubMed: https://pubmed.ncbi.nlm.nih.gov/39321430/
    • MOTS-c reduces myostatin and muscle atrophy signaling. PubMed: https://pubmed.ncbi.nlm.nih.gov/33554779/
    • The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. PubMed: https://pubmed.ncbi.nlm.nih.gov/29983246/
    • The Mitochondrial-Derived Peptide MOTS-c Alleviates Radiation Pneumonitis via an Nrf2-Dependent Mechanism. PubMed: https://pubmed.ncbi.nlm.nih.gov/38790718/
    • Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection. PubMed: https://pubmed.ncbi.nlm.nih.gov/37788894/
    • Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases. PubMed: https://pubmed.ncbi.nlm.nih.gov/36824008/
    • The mitochondrial-derived peptide MOTS-c suppresses ferroptosis and alleviates acute lung injury induced by myocardial ischemia reperfusion via PPARγ signaling pathway. PubMed: https://pubmed.ncbi.nlm.nih.gov/37290680/
    • The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. PubMed: https://pubmed.ncbi.nlm.nih.gov/38206815/

    Research-use-only catalog access

    KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.

    Access catalog path
    Browse technical product pages

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides